Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy

Prostate Cancer and Prostatic Diseases volume 18, pages 43–48 (2015)Cite this article

Subjects

Abstract

Background:

To assess the efficacy and safety of LY500307, a selective estrogen receptor beta agonist, on lower urinary tract symptoms (LUTS) in patients with enlarged prostate secondary to BPH.

Methods:

In a randomized, double-blind, placebo-controlled, parallel phase 2, efficacy and safety study, eligible patients with moderate to severe LUTS and prostatic enlargement (⩾30 ml) were randomized to placebo or LY500307 at 1, 3, 10 and 25 mg once daily for 24 weeks. Primary efficacy end point was change in total International Prostate Symptoms Score (IPSS) after 24 weeks. Secondary end points included changes in total prostate volume (TPV) that served as a proof of concept end point, as well as IPSS quality of life, maximum peak urine flow rate (Qmax) and PSA and safety (adverse events, laboratory test).

Results:

A total of 414 patients were randomized when the study was terminated because of insufficient TPV reduction, based on a priori defined interim analysis. The IPSS mean change from baseline to end point was −3.4±6.8 in the placebo group and −1.3±6.6, −2.6±7.0, −3.7±6.7 and −4.4±5.7 in the 1, 3, 10 and 25 mg LY500307-treated groups, respectively (P>0.05). Similarly, no treatment effect was observed for any of the secondary efficacy measures. Incidence of adverse events was comparable between treatment groups, and no clinically meaningful changes in laboratory tests were observed.

Conclusions:

LY500307 was well tolerated in BPH patients with LUTS at doses up to 25 mg once daily for 24 weeks. The study was terminated early because of inadequate efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Roehrborn CG . Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20: S11.

    Article  PubMed  Google Scholar 

  2. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387.

    Article  CAS  PubMed  Google Scholar 

  3. Weihua Z, Lathe R, Warner M, Gustafsson JA . An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99: 13589.

    Article  PubMed  Google Scholar 

  4. Martin C, Ross M, Chapman KE, Andrew R, Bollina P, Seckl JR et al. CYP7B generates a selective estrogen receptor beta agonist in human prostate. J Clin Endocrinol Metab 2004; 89: 2928.

    Article  CAS  PubMed  Google Scholar 

  5. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M et al. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 2004; 101: 9375.

    Article  CAS  PubMed  Google Scholar 

  6. Alonso-Magdalena P, Brössner C, Reiner A, Cheng G, Sugiyama N, Warner M et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA 2009; 106: 2859.

    Article  CAS  PubMed  Google Scholar 

  7. Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA et al. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem 2006; 49: 6155.

    Article  CAS  PubMed  Google Scholar 

  8. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS . Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 1323.

    Article  CAS  PubMed  Google Scholar 

  9. Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentriguge. Clin Chem 1972; 18: 499–502.

    CAS  Google Scholar 

  10. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Aloker K, Morrill B et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616–621.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

All authors have materially participated in the research and preparation of this manuscript and have approved this final version. The authors thank John D. Patton, MHA, MPH (Eli Lilly, Indianapolis, IN, USA) for assistance in preparing this manuscript.

Author information

Authors and Affiliations

  1. UT Southwestern Medical Center at Dallas, Dallas, TX, USA

    C G Roehrborn

  2. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

    M E Spann, S L Myers, C R Serviss, L Hu & Y Jin

Authors
  1. C G Roehrborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M E Spann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S L Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C R Serviss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Jin.

Ethics declarations

Competing interests

CG Roehrborn is a paid consultant of Eli Lilly and Company. Y Jin, ME Spann, SL Myers, CR Serviss and L Hu are fulltime employees and hold stocks and/or stock options with Eli Lilly and Company.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roehrborn, C., Spann, M., Myers, S. et al. Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. Prostate Cancer Prostatic Dis 18, 43–48 (2015). https://doi.org/10.1038/pcan.2014.43

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2014.43

This article is cited by

Search

Advanced search

Quick links